Oral hypoglycaemic agents (OHA) prescribed to patients after terminating rosiglitazone on 23 September 2010 or later
| Aarhus University Prescription Database, northern Denmark (n=474*) | General Practice Research Database, United Kingdom (n=2810†) | |||
|---|---|---|---|---|
| Number | Per cent (95% CI) | Number | Per cent (95% CI) | |
| Metformin | 269 | 57 (52 to 61) | 1136 | 42 (40 to 44) |
| Glimepiride | 84 | 18 (14 to 21) | 57 | 2.1 (1.6 to 2.7) |
| Metformin+sitagliptin | 49 | 10 (7.6 to 13) | ||
| Sitagliptin | 45 | 9.5 (6.9 to 12) | 103 | 3.8 (3.1 to 4.6) |
| Metformin+vildagliptin | 35 | 7.4 (5.0 to 9.7) | ||
| Liraglutide | 26 | 5.5 (3.4 to 7.5) | ||
| Pioglitazone | 21 | 4.4 (2.6 to 6.3) | 641 | 24 (22 to 25) |
| Pioglitazone+metformin | 394 | 14 (13 to 16) | ||
| Gliclazide | 17 | 3.6 (1.9 to 5.3) | 351 | 13 (12 to 14) |
| Glibenclamide | 8 | 1.7 (0.5 to 2.8) | 16 | 0.6 (0.4 to 1.0) |
| Saxagliptin | 8 | 1.7 (0.5 to 2.8) | ||
| Glipizide | 4 | 0.8 (0.1 to 1.7) | 9 | 0.3 (0.2 to 0.6) |
| Vildagliptin | 4 | 0.8 (0.1 to 1.7) | ||
| Repaglinide | 3 | 0.6 (0.1 to 1.3) | 2 | 0.1 (0.0 to 0.3) |
| Exenatide | 3 | 0.6 (0.1 to 1.3) | ||
| Acarbose | 2 | 0.4 (0.1 to 1.0) | 4 | 0.2 (0.1 to 0.4) |
| Tolbutamide | 1 | 0.2 (0.1 to 0.6) | 9 | 0.3 (0.2 to 0.6) |
*Eighty-three patients had no record of another OHA after the last rosiglitazone prescription.
†Eighty-eight patients had no record of another OHA after the last rosiglitazone prescription.